Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

Subarachnoid Hemorrhage Clinical Trial

Official title:

Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01799018
• Other study ID #: IRB#225490
• Status: Completed
• Phase: N/A
• First received: December 12, 2012
• Last updated: November 19, 2014
• Start date: April 2011
• Est. completion date: June 2013

Study information

• Verified date: November 2014
• Source: State University of New York - Upstate Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the role of Proteomics and Metallomics in Cerebral Vasospasm following Subarachnoid Hemorrhage

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: June 2013
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 89 Years

Eligibility

Inclusion Criteria:

• Non traumatic SAH documented by CT scan

• Patient with SAH who would need external ventricular drain (EVD) for the management of hydrocephalus

• Patients with normal pressure Hydrocephalus that require an external drain

• Control (non - hemorrhagic) group - CSF collected from patients with posterior fossa tumor or stroke with EVD in place for the management of hydrocephalus.

Exclusion Criteria:

• Recent infection within last 1 month of presentation- can increase inflammatory markers

• Recent surgery or acute myocardial infarction within last 1 month of presentation

• Age > 89 years or < 18 years

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cerebral Vasospasm
• Hemorrhage
• Hydrocephalus
• Subarachnoid Hemorrhage
• Vasospasm, Intracranial

Locations

Country	Name	City	State
United States	State University of New York Upstate Medical University	Syracuse	New York

Sponsors (1)

Lead Sponsor	Collaborator
State University of New York - Upstate Medical University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Protein identification and concentration		For the duration of CSF drainage, or until the 21st day after admission.	No
Primary	Metal ion identification and concentration		For the duration of CSF drainage, or until the 21st day after admission.	No